Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

Pancreatic Adenocarcinoma, Version 1.2019.

Tempero MA, Malafa MP, Chiorean EG, Czito B, Scaife C, Narang AK, Fountzilas C, Wolpin BM, Al-Hawary M, Asbun H, Behrman SW, Benson AB, Binder E, Cardin DB, Cha C, Chung V, Dillhoff M, Dotan E, Ferrone CR, Fisher G, Hardacre J, Hawkins WG, Ko AH, LoConte N, Lowy AM, Moravek C, Nakakura EK, O'Reilly EM, Obando J, Reddy S, Thayer S, Wolff RA, Burns JL, Zuccarino-Catania G.

J Natl Compr Canc Netw. 2019 Mar 1;17(3):202-210. doi: 10.6004/jnccn.2019.0014.

PMID:
30865919
2.

Hypervascular lesions of the pancreas: Think before you act.

Wcislak SM, Stiles ZE, Deneve JL, Glazer ES, Behrman SW, Farooq FT, Dickson PV.

Am J Surg. 2018 Nov 27. pii: S0002-9610(18)31212-1. doi: 10.1016/j.amjsurg.2018.11.021. [Epub ahead of print]

PMID:
30509457
3.

Long-Term Implications of Unplanned Conversion During Laparoscopic Liver Resection for Hepatocellular Carcinoma.

Stiles ZE, Glazer ES, Deneve JL, Shibata D, Behrman SW, Dickson PV.

Ann Surg Oncol. 2019 Jan;26(1):282-289. doi: 10.1245/s10434-018-7073-6. Epub 2018 Nov 19.

PMID:
30456682
4.

Outcomes Following Resection of Hepatocellular Carcinoma in the Absence of Cirrhosis.

Lewis RH, Glazer ES, Bittenbinder DM, O'Brien T, Deneve JL, Shibata D, Behrman SW, Vanatta JM, Satapathy SK, Dickson PV.

J Gastrointest Cancer. 2018 Aug 16. doi: 10.1007/s12029-018-0152-x. [Epub ahead of print]

PMID:
30117090
5.

Transmembrane mucin MUC13 distinguishes intraductal papillary mucinous neoplasms from non-mucinous cysts and is associated with high-risk lesions.

Stiles ZE, Khan S, Patton KT, Jaggi M, Behrman SW, Chauhan SC.

HPB (Oxford). 2019 Jan;21(1):87-95. doi: 10.1016/j.hpb.2018.07.009. Epub 2018 Aug 14.

PMID:
30115565
6.

Desmoplastic small round cell tumor: A nationwide study of a rare sarcoma.

Stiles ZE, Dickson PV, Glazer ES, Murphy AJ, Davidoff AM, Behrman SW, Bishop MW, Martin MG, Deneve JL.

J Surg Oncol. 2018 Jun;117(8):1759-1767. doi: 10.1002/jso.25071. Epub 2018 Jun 7.

PMID:
29878371
7.

The impact of unplanned conversion to an open procedure during minimally invasive pancreatectomy.

Stiles ZE, Dickson PV, Deneve JL, Glazer ES, Dong L, Wan JY, Behrman SW.

J Surg Res. 2018 Jul;227:168-177. doi: 10.1016/j.jss.2018.02.028. Epub 2018 Mar 19.

PMID:
29804849
8.

Ampullary adenocarcinoma: Defining predictors of survival and the impact of adjuvant therapy following surgical resection for stage I disease.

Stiles ZE, Behrman SW, Deneve JL, Glazer ES, Dong L, Wan JY, Martin MG, Dickson PV.

J Surg Oncol. 2018 Jun;117(7):1500-1508. doi: 10.1002/jso.25021. Epub 2018 Mar 8.

PMID:
29518820
9.

Molecular Alterations Associated with DNA Repair in Pancreatic Adenocarcinoma Are Associated with Sites of Recurrence.

Ferguson MD, Dong L, Wan J, Deneve JL, Dickson PV, Behrman SW, Shibata D, Martin MG, Glazer ES.

J Gastrointest Cancer. 2018 Feb 10. doi: 10.1007/s12029-018-0073-8. [Epub ahead of print]

PMID:
29427136
10.

Clinical significance of MUC13 in pancreatic ductal adenocarcinoma.

Khan S, Zafar N, Khan SS, Setua S, Behrman SW, Stiles ZE, Yallapu MM, Sahay P, Ghimire H, Ise T, Nagata S, Wang L, Wan JY, Pradhan P, Jaggi M, Chauhan SC.

HPB (Oxford). 2018 Jun;20(6):563-572. doi: 10.1016/j.hpb.2017.12.003. Epub 2018 Jan 17.

PMID:
29352660
11.

Risk Factors and Mitigation Strategies for Pancreatic Fistula After Distal Pancreatectomy: Analysis of 2026 Resections From the International, Multi-institutional Distal Pancreatectomy Study Group.

Ecker BL, McMillan MT, Allegrini V, Bassi C, Beane JD, Beckman RM, Behrman SW, Dickson EJ, Callery MP, Christein JD, Drebin JA, Hollis RH, House MG, Jamieson NB, Javed AA, Kent TS, Kluger MD, Kowalsky SJ, Maggino L, Malleo G, Valero V 3rd, Velu LKP, Watkins AA, Wolfgang CL, Zureikat AH, Vollmer CM Jr.

Ann Surg. 2019 Jan;269(1):143-149. doi: 10.1097/SLA.0000000000002491.

PMID:
28857813
12.

Pancreatogastrostomy Vs. Pancreatojejunostomy: a Risk-Stratified Analysis of 5316 Pancreatoduodenectomies.

Ecker BL, McMillan MT, Maggino L, Allegrini V, Asbun HJ, Ball CG, Bassi C, Beane JD, Behrman SW, Berger AC, Bloomston M, Callery MP, Christein JD, Dickson E, Dixon E, Drebin JA, Castillo CF, Fisher WE, Fong ZV, Haverick E, Hollis RH, House MG, Hughes SJ, Jamieson NB, Kent TS, Kowalsky SJ, Kunstman JW, Malleo G, Salem RR, Soares KC, Valero V 3rd, Watkins AA, Wolfgang CL, Zureikat AH, Vollmer CM Jr.

J Gastrointest Surg. 2018 Jan;22(1):68-76. doi: 10.1007/s11605-017-3547-2. Epub 2017 Aug 24. No abstract available.

PMID:
28840459
13.

Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

Tempero MA, Malafa MP, Al-Hawary M, Asbun H, Bain A, Behrman SW, Benson AB 3rd, Binder E, Cardin DB, Cha C, Chiorean EG, Chung V, Czito B, Dillhoff M, Dotan E, Ferrone CR, Hardacre J, Hawkins WG, Herman J, Ko AH, Komanduri S, Koong A, LoConte N, Lowy AM, Moravek C, Nakakura EK, O'Reilly EM, Obando J, Reddy S, Scaife C, Thayer S, Weekes CD, Wolff RA, Wolpin BM, Burns J, Darlow S.

J Natl Compr Canc Netw. 2017 Aug;15(8):1028-1061. doi: 10.6004/jnccn.2017.0131.

PMID:
28784865
14.

Predictors and implications of unplanned conversion during minimally invasive hepatectomy: an analysis of the ACS-NSQIP database.

Stiles ZE, Behrman SW, Glazer ES, Deneve JL, Dong L, Wan JY, Dickson PV.

HPB (Oxford). 2017 Nov;19(11):957-965. doi: 10.1016/j.hpb.2017.06.012. Epub 2017 Jul 29.

15.

A Prospective Randomized Multicenter Trial of Distal Pancreatectomy With and Without Routine Intraperitoneal Drainage.

Van Buren G 2nd, Bloomston M, Schmidt CR, Behrman SW, Zyromski NJ, Ball CG, Morgan KA, Hughes SJ, Karanicolas PJ, Allendorf JD, Vollmer CM Jr, Ly Q, Brown KM, Velanovich V, Winter JM, McElhany AL, Muscarella P 2nd, Schmidt CM, House MG, Dixon E, Dillhoff ME, Trevino JG, Hallet J, Coburn NSG, Nakeeb A, Behrns KE, Sasson AR, Ceppa EP, Abdel-Misih SRZ, Riall TS, Silberfein EJ, Ellison EC, Adams DB, Hsu C, Tran Cao HS, Mohammed S, VillafaƱe-Ferriol N, Barakat O, Massarweh NN, Chai C, Mendez-Reyes JE, Fang A, Jo E, Mo Q, Fisher WE.

Ann Surg. 2017 Sep;266(3):421-431. doi: 10.1097/SLA.0000000000002375.

PMID:
28692468
16.

Characterization and Optimal Management of High-risk Pancreatic Anastomoses During Pancreatoduodenectomy.

Ecker BL, McMillan MT, Asbun HJ, Ball CG, Bassi C, Beane JD, Behrman SW, Berger AC, Dickson EJ, Bloomston M, Callery MP, Christein JD, Dixon E, Drebin JA, Castillo CF, Fisher WE, Fong ZV, Haverick E, Hollis RH, House MG, Hughes SJ, Jamieson NB, Javed AA, Kent TS, Kowalsky SJ, Kunstman JW, Malleo G, Poruk KE, Salem RR, Schmidt CR, Soares K, Stauffer JA, Valero V, Velu LKP, Watkins AA, Wolfgang CL, Zureikat AH, Vollmer CM Jr.

Ann Surg. 2018 Apr;267(4):608-616. doi: 10.1097/SLA.0000000000002327.

PMID:
28594741
17.

Does Hyperbilirubinemia Contribute to Adverse Patient Outcomes Following Pancreatoduodenectomy?

Dolejs S, Zarzaur BL, Zyromski NJ, Pitt HA, Riall TS, Hall BL, Behrman SW.

J Gastrointest Surg. 2017 Apr;21(4):647-656. doi: 10.1007/s11605-017-3381-6. Epub 2017 Feb 15.

PMID:
28205125
18.

Pancreas fistula risk prediction: implications for hospital costs and payments.

Abbott DE, Tzeng CW, McMillan MT, Callery MP, Kent TS, Christein JD, Behrman SW, Schauer DP, Hanseman DJ, Eckman MH, Vollmer CM.

HPB (Oxford). 2017 Feb;19(2):140-146. doi: 10.1016/j.hpb.2016.10.016. Epub 2016 Nov 21.

19.

miRNA nanotherapeutics for cancer.

Ganju A, Khan S, Hafeez BB, Behrman SW, Yallapu MM, Chauhan SC, Jaggi M.

Drug Discov Today. 2017 Feb;22(2):424-432. doi: 10.1016/j.drudis.2016.10.014. Epub 2016 Nov 1. Review.

20.

Externalized Stents for Pancreatoduodenectomy Provide Value Only in High-Risk Scenarios.

McMillan MT, Ecker BL, Behrman SW, Callery MP, Christein JD, Drebin JA, Fraker DL, Kent TS, Lee MK, Roses RE, Sprys MH, Vollmer CM Jr.

J Gastrointest Surg. 2016 Dec;20(12):2052-2062. Epub 2016 Oct 11.

PMID:
27730401
21.

Restitution of Tumor Suppressor MicroRNA-145 Using Magnetic Nanoformulation for Pancreatic Cancer Therapy.

Setua S, Khan S, Yallapu MM, Behrman SW, Sikander M, Khan SS, Jaggi M, Chauhan SC.

J Gastrointest Surg. 2017 Jan;21(1):94-105. doi: 10.1007/s11605-016-3222-z. Epub 2016 Aug 9.

22.

Incorporation of Procedure-specific Risk Into the ACS-NSQIP Surgical Risk Calculator Improves the Prediction of Morbidity and Mortality After Pancreatoduodenectomy.

McMillan MT, Allegrini V, Asbun HJ, Ball CG, Bassi C, Beane JD, Behrman SW, Berger AC, Bloomston M, Callery MP, Christein JD, Dickson E, Dixon E, Drebin JA, Fernandez-Del Castillo C, Fisher WE, Fong ZV, Haverick E, Hollis RH, House MG, Hughes SJ, Jamieson NB, Kent TS, Kowalsky SJ, Kunstman JW, Malleo G, McElhany AL, Salem RR, Soares KC, Sprys MH, Valero V 3rd, Watkins AA, Wolfgang CL, Zureikat AH, Vollmer CM Jr.

Ann Surg. 2017 May;265(5):978-986. doi: 10.1097/SLA.0000000000001796.

PMID:
27232260
23.

PSMA targeted docetaxel-loaded superparamagnetic iron oxide nanoparticles for prostate cancer.

Nagesh PKB, Johnson NR, Boya VKN, Chowdhury P, Othman SF, Khalilzad-Sharghi V, Hafeez BB, Ganju A, Khan S, Behrman SW, Zafar N, Chauhan SC, Jaggi M, Yallapu MM.

Colloids Surf B Biointerfaces. 2016 Aug 1;144:8-20. doi: 10.1016/j.colsurfb.2016.03.071. Epub 2016 Mar 26.

24.

Risk-adjusted Outcomes of Clinically Relevant Pancreatic Fistula Following Pancreatoduodenectomy: A Model for Performance Evaluation.

McMillan MT, Soi S, Asbun HJ, Ball CG, Bassi C, Beane JD, Behrman SW, Berger AC, Bloomston M, Callery MP, Christein JD, Dixon E, Drebin JA, Castillo CF, Fisher WE, Fong ZV, House MG, Hughes SJ, Kent TS, Kunstman JW, Malleo G, Miller BC, Salem RR, Soares K, Valero V, Wolfgang CL, Vollmer CM Jr.

Ann Surg. 2016 Aug;264(2):344-52. doi: 10.1097/SLA.0000000000001537.

PMID:
26727086
25.

Comparing the burden of pancreatic fistulas after pancreatoduodenectomy and distal pancreatectomy.

McMillan MT, Christein JD, Callery MP, Behrman SW, Drebin JA, Hollis RH, Kent TS, Miller BC, Sprys MH, Watkins AA, Strasberg SM, Vollmer CM Jr.

Surgery. 2016 Apr;159(4):1013-22. doi: 10.1016/j.surg.2015.10.028. Epub 2015 Dec 6.

PMID:
26670325
26.

Follicular pancreatitis: a distinct form of chronic pancreatitis-an additional mimic of pancreatic neoplasms.

Gupta RK, Xie BH, Patton KT, Lisovsky M, Burks E, Behrman SW, Klimstra D, Deshpande V.

Hum Pathol. 2016 Feb;48:154-62. doi: 10.1016/j.humpath.2015.09.017. Epub 2015 Oct 3.

27.

Surgical management of complicated pancreatic pseudocysts after acute pancreatitis.

Marino KA, Hendrick LE, Behrman SW.

Am J Surg. 2016 Jan;211(1):109-14. doi: 10.1016/j.amjsurg.2015.07.020. Epub 2015 Oct 24.

PMID:
26507289
28.

The Characterization and Prediction of ISGPF Grade C Fistulas Following Pancreatoduodenectomy.

McMillan MT, Vollmer CM Jr, Asbun HJ, Ball CG, Bassi C, Beane JD, Berger AC, Bloomston M, Callery MP, Christein JD, Dixon E, Drebin JA, Castillo CF, Fisher WE, Fong ZV, Haverick E, House MG, Hughes SJ, Kent TS, Kunstman JW, Malleo G, McElhany AL, Salem RR, Soares K, Sprys MH, Valero V 3rd, Watkins AA, Wolfgang CL, Behrman SW.

J Gastrointest Surg. 2016 Feb;20(2):262-76. doi: 10.1007/s11605-015-2884-2. Epub 2015 Jul 11.

PMID:
26162925
29.

Nanoparticle formulation of ormeloxifene for pancreatic cancer.

Khan S, Chauhan N, Yallapu MM, Ebeling MC, Balakrishna S, Ellis RT, Thompson PA, Balabathula P, Behrman SW, Zafar N, Singh MM, Halaweish FT, Jaggi M, Chauhan SC.

Biomaterials. 2015;53:731-43. doi: 10.1016/j.biomaterials.2015.02.082. Epub 2015 Mar 26.

30.

Ormeloxifene suppresses desmoplasia and enhances sensitivity of gemcitabine in pancreatic cancer.

Khan S, Ebeling MC, Chauhan N, Thompson PA, Gara RK, Ganju A, Yallapu MM, Behrman SW, Zhao H, Zafar N, Singh MM, Jaggi M, Chauhan SC.

Cancer Res. 2015 Jun 1;75(11):2292-304. doi: 10.1158/0008-5472.CAN-14-2397. Epub 2015 Apr 3. Erratum in: Cancer Res. 2018 May 1;78(9):2444.

31.

Quantifying the burden of complications following total pancreatectomy using the postoperative morbidity index: a multi-institutional perspective.

Datta J, Lewis RS Jr, Strasberg SM, Hall BL, Allendorf JD, Beane JD, Behrman SW, Callery MP, Christein JD, Drebin JA, Epelboym I, He J, Pitt HA, Winslow E, Wolfgang C, Lee MK 4th, Vollmer CM Jr.

J Gastrointest Surg. 2015 Mar;19(3):506-15. doi: 10.1007/s11605-014-2706-y. Epub 2014 Dec 2.

PMID:
25451733
32.

MicroRNA-145 targets MUC13 and suppresses growth and invasion of pancreatic cancer.

Khan S, Ebeling MC, Zaman MS, Sikander M, Yallapu MM, Chauhan N, Yacoubian AM, Behrman SW, Zafar N, Kumar D, Thompson PA, Jaggi M, Chauhan SC.

Oncotarget. 2014 Sep 15;5(17):7599-609.

33.

Establishing a quantitative benchmark for morbidity in pancreatoduodenectomy using ACS-NSQIP, the Accordion Severity Grading System, and the Postoperative Morbidity Index.

Vollmer CM Jr, Lewis RS, Hall BL, Allendorf JD, Beane JD, Behrman SW, Callery MP, Christein JD, Drebin JA, Epelboym I, He J, Pitt HA, Winslow E, Wolfgang C, Strasberg SM.

Ann Surg. 2015 Mar;261(3):527-36. doi: 10.1097/SLA.0000000000000843.

PMID:
25268299
34.

The value of drains as a fistula mitigation strategy for pancreatoduodenectomy: something for everyone? Results of a randomized prospective multi-institutional study.

McMillan MT, Fisher WE, Van Buren G 2nd, McElhany A, Bloomston M, Hughes SJ, Winter J, Behrman SW, Zyromski NJ, Velanovich V, Brown K, Morgan KA, Vollmer C.

J Gastrointest Surg. 2015 Jan;19(1):21-30; discussion 30-1. doi: 10.1007/s11605-014-2640-z. Epub 2014 Sep 3.

PMID:
25183409
35.

Routine drainage of the operative bed following elective distal pancreatectomy does not reduce the occurrence of complications.

Behrman SW, Zarzaur BL, Parmar A, Riall TS, Hall BL, Pitt HA.

J Gastrointest Surg. 2015 Jan;19(1):72-9; discussion 79. doi: 10.1007/s11605-014-2608-z. Epub 2014 Aug 13.

36.

Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines.

Tempero MA, Malafa MP, Behrman SW, Benson AB 3rd, Casper ES, Chiorean EG, Chung V, Cohen SJ, Czito B, Engebretson A, Feng M, Hawkins WG, Herman J, Hoffman JP, Ko A, Komanduri S, Koong A, Lowy AM, Ma WW, Merchant NB, Mulvihill SJ, Muscarella P 2nd, Nakakura EK, Obando J, Pitman MB, Reddy S, Sasson AR, Thayer SP, Weekes CD, Wolff RA, Wolpin BM, Burns JL, Freedman-Cass DA.

J Natl Compr Canc Netw. 2014 Aug;12(8):1083-93.

PMID:
25099441
37.

Prophylactic octreotide for pancreatoduodenectomy: more harm than good?

McMillan MT, Christein JD, Callery MP, Behrman SW, Drebin JA, Kent TS, Miller BC, Lewis RS Jr, Vollmer CM Jr.

HPB (Oxford). 2014 Oct;16(10):954-62. doi: 10.1111/hpb.12314. Epub 2014 Jul 10.

38.

Defining the post-operative morbidity index for distal pancreatectomy.

Lee MK 4th, Lewis RS, Strasberg SM, Hall BL, Allendorf JD, Beane JD, Behrman SW, Callery MP, Christein JD, Drebin JA, Epelboym I, He J, Pitt HA, Winslow E, Wolfgang C, Vollmer CM Jr.

HPB (Oxford). 2014 Oct;16(10):915-23. doi: 10.1111/hpb.12293. Epub 2014 Jun 16.

39.

Nanoways to overcome docetaxel resistance in prostate cancer.

Ganju A, Yallapu MM, Khan S, Behrman SW, Chauhan SC, Jaggi M.

Drug Resist Updat. 2014 Apr;17(1-2):13-23. doi: 10.1016/j.drup.2014.04.001. Epub 2014 Apr 5. Review.

40.

Multi-visceral resection of locally advanced extra-pancreatic carcinoma.

Cullinan DR, Behrman SW.

Hepatobiliary Pancreat Dis Int. 2014 Apr;13(2):198-202.

PMID:
24686548
41.

Distal cholangiocarcinoma.

Dickson PV, Behrman SW.

Surg Clin North Am. 2014 Apr;94(2):325-42. doi: 10.1016/j.suc.2013.12.004. Review.

PMID:
24679424
42.

A randomized prospective multicenter trial of pancreaticoduodenectomy with and without routine intraperitoneal drainage.

Van Buren G 2nd, Bloomston M, Hughes SJ, Winter J, Behrman SW, Zyromski NJ, Vollmer C, Velanovich V, Riall T, Muscarella P, Trevino J, Nakeeb A, Schmidt CM, Behrns K, Ellison EC, Barakat O, Perry KA, Drebin J, House M, Abdel-Misih S, Silberfein EJ, Goldin S, Brown K, Mohammed S, Hodges SE, McElhany A, Issazadeh M, Jo E, Mo Q, Fisher WE.

Ann Surg. 2014 Apr;259(4):605-12. doi: 10.1097/SLA.0000000000000460.

PMID:
24374513
43.

A multi-institutional external validation of the fistula risk score for pancreatoduodenectomy.

Miller BC, Christein JD, Behrman SW, Drebin JA, Pratt WB, Callery MP, Vollmer CM Jr.

J Gastrointest Surg. 2014 Jan;18(1):172-79; discussion 179-80. doi: 10.1007/s11605-013-2337-8. Epub 2013 Sep 4.

PMID:
24002771
44.

Assessing the impact of a fistula after a pancreaticoduodenectomy using the Post-operative Morbidity Index.

Miller BC, Christein JD, Behrman SW, Callery MP, Drebin JA, Kent TS, Pratt WB, Lewis RS Jr, Vollmer CM Jr.

HPB (Oxford). 2013 Oct;15(10):781-8. doi: 10.1111/hpb.12131. Epub 2013 Jul 22.

45.

Modern concepts in pancreatic surgery.

Behrman SW, Martin RF.

Surg Clin North Am. 2013 Jun;93(3):xv-xvi. doi: 10.1016/j.suc.2013.03.001. Epub 2013 Apr 3. No abstract available.

PMID:
23632156
46.

Management of pancreatic neuroendocrine tumors.

Dickson PV, Behrman SW.

Surg Clin North Am. 2013 Jun;93(3):675-91. doi: 10.1016/j.suc.2013.02.001. Epub 2013 Apr 3. Review.

PMID:
23632152
47.

miRNA profiling in pancreatic cancer and restoration of chemosensitivity.

Singh S, Chitkara D, Kumar V, Behrman SW, Mahato RI.

Cancer Lett. 2013 Jul 1;334(2):211-20. doi: 10.1016/j.canlet.2012.10.008. Epub 2012 Oct 13.

PMID:
23073476
48.

Role of miRNA and cancer stem cells in chemoresistance and pancreatic cancer treatment.

Danquah M, Singh S, Behrman SW, Mahato RI.

Expert Opin Drug Deliv. 2012 Dec;9(12):1443-7. doi: 10.1517/17425247.2012.722079. Epub 2012 Sep 6. No abstract available.

PMID:
22954290
49.

Toward defining grade C pancreatic fistula following pancreaticoduodenectomy: incidence, risk factors, management and outcome.

Denbo JW, Orr WS, Zarzaur BL, Behrman SW.

HPB (Oxford). 2012 Sep;14(9):589-93. doi: 10.1111/j.1477-2574.2012.00486.x. Epub 2012 May 28. Review.

50.

Micellar delivery of cyclopamine and gefitinib for treating pancreatic cancer.

Chitkara D, Singh S, Kumar V, Danquah M, Behrman SW, Kumar N, Mahato RI.

Mol Pharm. 2012 Aug 6;9(8):2350-7. doi: 10.1021/mp3002792. Epub 2012 Jul 23.

PMID:
22780906

Supplemental Content

Loading ...
Support Center